Core Insights - Stereotaxis (STXS) has partnered with CardioFocus to develop the first robotic Pulsed Field Ablation (PFA) system for treating cardiac arrhythmias, combining robotic precision with advanced PFA technology to enhance clinical use and commercialization [1][6][8] Company Summary - The collaboration is expected to leverage the strengths of both companies, enhancing treatment options in electrophysiology and expanding their presence in the growing cardiac care market [2][4] - Stereotaxis aims to integrate CardioFocus's CE-marked Centauri PFA System into its robotic platform, enhancing its product portfolio and creating new revenue streams in the cardiac ablation market [4][11] - STXS currently has a market capitalization of $279.6 million and reported an earnings surprise of 28.6% in the last quarter [5] Market Trends - The global pulsed field ablation market is projected to grow from an estimated size of $913.1 million in 2024 at a CAGR of 33.1% from 2025 to 2030, driven by the rising prevalence of atrial fibrillation and the adoption of minimally invasive procedures [12]